Forecast

The analysts' average price target is €11.76 (+61.76%). The median is €10.40 (+43.05%).

Buy	19
Hold	6
Sell	1

News Go to news feed

Arvinas focuses on PROTAC pipeline and prepares four clinical programs for data

At the Cantor Fitzgerald conference, Arvinas said the strategic shift from commercialization to advancing its own PROTAC pipeline is largely complete. The company’s cash runway extends into the second half of 2028, enough capital to advance four clinical programs to key Phase I data. Near-term catalysts are data for ARV-393 (lymphomas), LRRK2-102 (neurodegeneration), ARV-027 (Kennedy disease) and ARV-6723 (immuno-oncology); KRAS‑G12D is partner-led only and the PSP program has been pushed regulatory-wise to 2027. The commercial therapy VEPPANNU is being marketed by Rigel; milestone payments and tiered royalties are expected to provide additional revenue. » More on de.investing.com
Arvinas highlights pipeline and upcoming study data at Wells Fargo conference

Arvinas emphasized that with the commercial launch of Vepdegestrant the company is involved with a marketed product for the first time and that liquidity is sufficient through the second half of 2028. Management expects data from four clinical programs within 15 months, including ARV-393 (BCL6) and ARV-102 (LRRK2), is pursuing selective partnerships and will keep key programs such as SBMA in-house. The company sees continued development of its platform but warns of the usual regulatory, safety and execution risks that will determine near-term success. » More on de.investing.com
Arvinas: Q1 revenue plunges, EPS beats expectations and stock rises in premarket

Arvinas reported Q1 2026 revenue of $15.6 million (estimate $17.16 million, Q1 2025: $188.8 million), mainly due to the restructuring of the partnership with Pfizer. Earnings per share were -$0.90, beating the expected -$0.93. The company significantly cut R&D and general & administrative expenses, extended its cash runway into the second half of 2028, and points to FDA approval for VEPPANU as a key milestone. The stock rose 1.45% in premarket trading to $9.80. » More on de.investing.com

Financials

In the last quarter, ARVINAS INC. DL-,001 had revenue of €218.79m and net profit of €148.43m

(EUR)	June 2026	YoY
Revenue	218.79m	1,051.24%
Gross profit	210.9m	1,009.75%
Net profit	148.43m	385.86%
EBITDA	139.58m	373.74%

Fundamentals

Metric	Value
Market capitalization	€472.34m
Number of shares	64.52m
52-week high/low	€12.57 - €6.04
Dividends	No
Beta	1.76
P/E ratio	44.47
PEG ratio	-0.24
P/B ratio	0.97
P/S ratio	1.72

Company profile

Arvinas, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich mit der Entdeckung, Entwicklung und Vermarktung von Therapien zum Abbau von krankheitsverursachenden Proteinen beschäftigt. Zu seinen führenden Produktkandidaten gehört Bavdegalutamid, ein PROTAC-Proteinabbauer, der sich in der klinischen Phase I befindet und auf das Androgenrezeptor-Protein (AR) zur Behandlung von Männern mit metastasiertem kastrationsresistentem Prostatakrebs (mCRPC) abzielt; ARV-471, ein PROTAC-Proteinabbauer, der auf das Östrogenrezeptorprotein abzielt, für die Behandlung von Patienten mit metastasierendem ER-positivem/HER2-negativem Brustkrebs; und ARV-766, ein oral bioverfügbarer PROTAC-Proteinabbauer für die Behandlung von Männern mit mCRPC. Das Unternehmen arbeitet mit Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd. und der Bayer AG zusammen. Arvinas, Inc. wurde 2013 gegründet und hat seinen Sitz in New Haven, Connecticut.